Total
0
Shares
Sienna Senior Living (TSX:SIA) braces for  second wave
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • This integration will double the number of LTCs using the Writi platform
  • Writi’s SaaS-based Virtual Healthcare platform facilitates secure communication and documentation of resident care for LTCs
  • The platform includes telehealth, e-prescribe, e-billing, electronic order-processing, patient charting and integrates with EMRs
  • Jack Nathan Health, provides an exceptional level of patient care through a variety of medical services, technology, and programs
  • Jack Nathan Health (JNH) is up 1.37 per cent, trading at C$0.74 per share at 1 pm ET

Jack Nathan Health (JNH) subsidiary, Writi Inc, has secured the software installation for 15 new Long-Term Care (LTC) homes, representing over 1650 beds.

This integration will double the number of LTCs using the Writi platform and increase its recurring revenue install base to a total of 30 LTCs and over 3200 beds in Ontario.

Writi v2.0 delivers enhancements to speed and efficiency, across all modules, secure group conferencing video calling between Healthcare entities and a new and improved mobile app.

“These new integrations and expanding footprint are a reflection of the value that Writi’s Virtual Healthcare platform brings to LTCs in terms of improved communication and documentation,” said Chief Executive Officer of Jack Nathan Health, George Barakat.

“With Writi, we will continue to leverage JNH’s clinical expertise and parlay our technology roadmap with Writi’s superior LTC solutions to drive new opportunities and create recurring and sustainable revenue growth.”

Writi’s SaaS-based Virtual Healthcare platform facilitates secure communication and documentation of resident care for LTCs and is available on both desktop and mobile devices.

The cloud-based medication management software platform supports secure digital communication, record maintenance and workflow of resident-related orders and documentation. The platform includes telehealth, e-prescribe, e-billing, electronic order-processing, patient charting and integrates with Electronic Medical Records (EMRs).

With Writi’s Virtual Healthcare platform, a patient’s health record is securely accessible by local and remote healthcare partners; it reduces prescribing time and nursing order-processing time, drastically reducing the administrative burden on practitioners allowing them to focus on patient care.

Canada’s LTC system is strained by overcrowding and limited resources. Today, people over 65 make up 44 per cent of healthcare costs. There are over 700 LTC homes and over 1,000 senior care homes in Ontario alone. By 2036 a quarter of Canadians will be over 65 putting additional pressure on the entire Canadian healthcare system. 

Jack Nathan Medical Corp., operating as Jack Nathan Health, provides an exceptional level of patient care, made possible through patient-centric physicians, a variety of medical services, technology, and programs, designed to put patients first.

Jack Nathan Health (JNH) is up 1.37 per cent, trading at C$0.74 per share at 1 pm ET.

More From The Market Herald
Leveljump (TSXV:JUMP) to acquire Ontario clinics

" Leveljump (TSXV:JUMP) to acquire Ontario clinics

Leveljump Healthcare (JUMP) is set to acquire three Ontario diagnostic imaging clinics from a private vendor.
CloudMD (TSXV:DOC) announces a change of auditors and new board of director nominees

" CloudMD (TSXV:DOC) announces a change of auditors and new board of director nominees

CloudMD has nominated Duncan Hannay and Karen Adams to the company’s board of directors.
Psyence Group (CSE:PSYG) and Pure Extracts (CSE:PULL) form psychedelics joint venture

" Psyence Group (CSE:PSYG) and Pure Extracts (CSE:PULL) form psychedelics joint venture

Pure Extracts (PULL) and Psyence Group (PSYG) have formed a JV for psychedelic medicinal mushroom extracts.
PharmaDrug (CSE:PHRX) announces meeting with FDA

" PharmaDrug (CSE:PHRX) announces meeting with FDA

PharmaDrug (PHRX) has been granted a pre-investigational new drug meeting with the FDA for its COVID-19 treatment.